Pharmaceutical compositions comprising anti-teratogenic agents are disclosed. Additionally, pharmaceutical compositions comprising anti-neoplastic agents and anti-teratogenic agents are disclosed. Methods of assessing the teratogenicity of a compound are disclosed. The present invention further comprises applications of the aforementioned compositions and methods.
1. A method of inhibiting the teratogenicity of an anti-neoplastic agent, the method comprising administering a pharmaceutical composition comprising Noggin.